financetom
Business
financetom
/
Business
/
Constellation Brands Q2 EPS to Miss Views, Macro Factors to Affect Fiscal 2025, Morgan Stanley Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Constellation Brands Q2 EPS to Miss Views, Macro Factors to Affect Fiscal 2025, Morgan Stanley Says
Aug 29, 2024 8:55 AM

12:37 PM EDT, 08/26/2024 (MT Newswires) -- Constellation Brands' ( STZ ) earnings per share for fiscal Q2 and fiscal 2025 may fall below consensus, based on the data collected so far, Morgan Stanley said in a note Monday.

"[Constellation Brands' ( STZ )] volumes in scanner data have been weaker than expected quarter to date, with the convenience channel particularly soft as noted by other beverage companies, reflecting macro pressure on low to middle income consumers," the investment firm said.

The macro environment affecting beer sale is expected to linger and will probably impact full-year earnings as well, Morgan Stanley said, and a lack of investor interest will not help the cause.

The investment bank cut its EPS forecast for the beverage company to $4.03 from $4.14 for fiscal Q2 and to $13.52 from $13.71 for fiscal 2025, lower than the consensus of $4.10 and $13.72, respectively.

Beer shipments are expected to drop to 5.0% from 6.5% and depletions to drop to 3.9% from 5.5%.

Morgan Stanley lowered its price target for Constellation to $280 from $305 with an overweight rating.

Price: 243.95, Change: -1.23, Percent Change: -0.50

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Copyright 2023-2026 - www.financetom.com All Rights Reserved